The immunopathogenesis of meningococcal disease

Journal of Clinical Pathology

Volumn 56, Issue 6, 2003, Pages 417-422

  Kvalsvig, A J ^a   Unsworth, D J ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN A; INTERLEUKIN 10;

AGE DISTRIBUTION; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY DETECTION; ANTIGEN RECOGNITION; BACTERIAL INFECTION; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEFICIENCY; CYTOKINE RELEASE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; EPIDEMIC; GENE SEGREGATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; MEDICAL ASSESSMENT; MENINGOCOCCOSIS; MUCOSAL IMMUNITY; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEROPREVALENCE;

EID: 0038648662     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.56.6.417     Document Type: Review

References (123)

1. Cartwright K, Reilly S, White D, et al. Early treatment with parenteral penicillin in meningococcal disease. BMJ 1992;305:143-7.
2. Thorburn K, Baines P, Thomson A, et al. Mortality in severe meningococcal disease. Arch Dis Child 2001;85:382-5.
3. Booy R, Habibi P, Nadel S, et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 2001;85:386-90.
4. Scholten RJPM, Bijlmer HA, Valkenburg HA, et al. Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis. Epidemiol Infect 1994; 112:115-24.
5. Sørensen HT, Nielsen GL, Schønheyder HC, et al. Outcome of pre-hospital antibiotic treatment of meningococcal disease. J Clin Epidemiol 1998;51:717-21.
6. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr 1981;99:540-5.
7. Wylie PAL, Stevens D, Drake W, III, et al. Epidemiology and clinical management of meningococcal disease in west Gloucestershire: retrospective, population based study. BMJ 1997;315:774-9.
8. Strang JR, Pugh EJ. Meningococcal infections: reducing the case fatality rate by giving penicillin before admission to hospital. BMJ 1992;305:143.
9. Mercier J-C, Beaufils F, Hartmann J-F, et al. Hemodynamic patterns of meningococcal shock in children. Crit Care Med 1988;16:27-33.
10. Cartwright K, Ala'Aldeen DAA. Neisseria meningitidis: clinical aspects. J Infect 1997;34:15-19.
11. Leteurtre S, Leclerc F, Martinot A, et al. Can generic scores (pediatric risk of mortality and pediatric index of mortality) replace specific scores in predicting the outcome of presumed meningococcal septic shock in children? Crit Care Med 2001;29:1239-46.
12. Hazelzet JA, de Groot R, van Mierlo G, et al. Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect Immun 1998;66:5350-6.
13. Bone RC. Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Ann Intern Med 1991;114:332-3.
14. Bolt P, Britto J, Nadel S, et al. Meningococcal disease due to W135: fresh public health concerns. Arch Dis Child 2001;84:90-1.
15. PHLS. Meningitis. 1999/2000 review of communicable diseases in England and Wales. 2000:1-10.
16. Caugant DA, Høiby EA, Magnus P, et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol 1994;32:323-30.
17. Neal KR, Nguyen-Van-Tam JS, Jeffrey N, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: a cross sectional study. BMJ 2000;320:846-9.
18. Sim RJ, Harrison MM, Moxon ER, et al. Underestimation of meningococci in tonsillar tissue by nasopharyngeal swabbing. Lancet 2000;356:1653-4.
19. Virji M. Mechanisms of microbial adhesion; the paradigm of Neisseriae. In: McCrae MA, Saunders JR, Smyth CJ, et al, eds. Molecular aspects of host-pathogen interaction. Cambridge: Cambridge University Press, 1997:95-110.
20. Billker O, Popp A, Gray-Owen SD, et al. The structural basis of CEACAM-receptor targeting by neisserial Opa proteins. Trends Microbiol 2000;8:258-60;discussion:260-1.
21. de Vries FP, van der Ende A, van Putten JPM, et al. Invasion of primary nasopharyngeal epithelial cells by Neisseria meningitidis is controlled by phase variation of multiple surface antigens. Infect Immun 1996;64:2998-3006.
22. Bayliss CD, Field D, Moxon ER. The simple sequence contingency loci of Haemophilus influenzae and Neisseria meningitidis. J Clin Invest 2001;107:657-62.
23. Read RC, Zimmerli S, Broaddus VC, et al. The (α2>8)-linked polysialic acid capsule of group B Neisseria meningitidis modifies multiple steps during interaction with human macrophages. Infect Immun 1996;64:3210-17.
24. Lindahl G, Sjöbring U, Johnsson E. Human complement regulators: a major target for pathogenic microorganisms. Curr Opin Immunol 2000;12:44-51.
25. Rautemaa R Meri S. Complement-resistance mechanisms of bacteria. Microbes Infect 1999;1:785-94.
26. Lorenzen D, Düx F, Wölk U, et al. Immunoglobulin A1 protease, an exoenzyme of pathogenic Neisseriae, is a potent inducer of proinflammatory cytokines. J Exp Med 1999; 190:1049-58.
27. Jack DL, Dodds AW, Anwar N, et al. Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B. J Immunol 1998;160:1346-53.
28. Jarvis GA, Griffiss JM. Human IgA1 initiates complement-mediated killing of Neisseria meningitidis. J Immunol 1989;143:1703-9.
29. Walport MJ. Complement: first of two parts. N Engl J Med 2001;344:1058-66.
30. Janeway CA, Jr, Travers P, Walport MJ, et al. Immunobiology: the immune system in health and disease. Edinburgh: Current Biology Publications/Garland/Churchill Livingstone, 1999.
31. Janeway CA, Jr. How the immune system works to protect the host from infection: a personal view. Proc Natl Acad Sci U S A 2001;98:7461-8.
32. Mathison JC, Tobias PS, Wolfson E, et al. Plasma lipopolysaccharide (LPS)-binding protein: a key component in macrophage recognition of gram-negative LPS. J Immunol 1992;149:200-6.
33. Noursadeghi M, Bickerstaff MCM, Gaflimore JR, et al. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc Natl Acad Sci U S A 2000;97:14584-9.
34. Jack DL, Klein N, Turner MW. Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev 2001;180:99.
35. Le Roy D, Di Padova F, Adachi Y, et al. Critical role of lipopolysaccharide-binding protein and CD14 in immune responses against gram-negative bacteria. J Immunol 2001;167:2759-65.
36. Ingalls RR, Heine H, Lien E, et al. Lipopolysaccharide recognition, CD 14, and lipopolysaccharide receptors. Infect Dis Clin North Am 1999;13:341-53.
37. Elsbach P, Weiss J. Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol 1998;10:45-9.
38. Neth O, Jack DL, Dodds AW, et al. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000;68:688-93.
39. Muzio M, Polentarutti N, Bosisio D, et al. Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J Leukoc Biol 2000;67:450-6.
40. Beutler B. Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol 2000;12:20-6.
41. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-7.
42. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000;406:782-7.
43. Pridmore AC, Wyllie DH, Abdillahi F, et al. A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via Toll-like receptor (TLR) 2 but not via TLR4/MD2. J Infect Dis 2001;183:89-96.
44. Massari P, Henneke P, Ho Y, et al. Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J Immunol 2002;168:1533-7.
45. Read RC, Pullin J, Gregory S, et al. A functional polymorphism of Toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis 2001;184:640-2.
46. Chow JC, Young DW, Golenbock DT, et al. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999;274:10689-92.
47. Vidarsson G, van der Pol WL, van den Elsen JMH, et al. Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J Immunol 2001;166:6250-6.
48. Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine 1984;63:243-73.
49. Bruce MG, Rosenstein NE, Capparella JM, et al. Risk factors for meningococcal disease in college students. JAMA 2001;286:688-93.
50. Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001;183:160-3.
51. Finne J, Bitter-Suermann D, Goridis C, et al. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987;138:4402-7.
52. Jódar L, Feavers IM, Salisbury D, et al. Development of vaccines against meningococcal disease. Lancet 2002;359:1499-5081.
53. MacLennan J. Meningococcal group C conjugate vaccines. Arch Dis Child 2001;84:383-6.
54. Peter G. Update on meningococcal vaccine. Pediatr Infect Dis 2001;20:311-12.
55. Ross SC, Rosenthal PJ, Berberich HM, et al. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J Infect Dis 1987;155:1266-75.
56. Jack DL, Jarvis GA, Booth CL, et al. Mannose-binding lectin accelerates complement activation and increases serum killing of Neisseria meningitidis serogroup C. J Infect Dis 2001;184:836-45.
57. Jack DL, Read RC, Tenner AJ, et al. Mannose-binding lectin regulates the inflammatory response of human professional phagocytes to Neisseria meningitidis serogroup B. J Infect Dis 2001;184:1152-62.
58. Jiang Q, Akashi S, Miyake K, et al. Cutting edge: lipopolysaccharide induces physical proximity between CD14 and Toll-like receptor (TLR4) prior to nuclear translocation of NF-κB. J Immunol 2000;165:3541-4.
59. Casey LC. Immunologic response to infection and its role in septic shock. Crit Care Clin 2000;16:193-213.
60. Waage A, Brandtzaeg P, Halstensen A, et al. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989;169:333-8.
61. Riordan FAI, Marzouk O, Thompson APJ, et al. Proinflammatory and anti-inflammatory cytokines in meningococcal disease. Arch Dis Child 1996;75:453-4.
62. van Deuren M, Brandtzaeg P, van der Meer J. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000;13:144-66.
63. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-8.
64. Lehmann AK, Gorringe AR, Reddin KM, et al. Human opsonins induced during meningococcal disease recognise transferrin binding protein complexes. Infect Immun 1999;67:6526-32.
65. van Deuren M, van der Vendongekrijg J, Vannier E, et al. The pattern of interleukin-1β (IL-1β) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections. Blood 1997;90:1101-8.
66. Parrillo JP. Pathogenetic mechonisms of septic shock. N Engl J Med 1993;328:1471-8.
67. Hack CE, Zeerleder S. The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 2001;29:S21-7.
68. Mirlashari MR, Høiby EA, Hoist J, et al. Outer membrane vesicles from Neisseria meningitidis: effects on tissue factor and plasminogen activator inhibitor-2 production in human monocytes. Thromb Res 2001;102:375-80.
69. Bernard GP, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
70. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-92.
71. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001;29:S99-106.
72. de Kleijn ED, Hazelzet JA, Kornelisse RF, et al. Pathophysiology of meningococcal sepsis in children. Eur J Pediatr 1998;157:869-80.
73. Briassoulis G, Narlioglou M, Zavras N, et al. Myocardial injury in meningococcus-induced purpura fulminans in children. Intensive Care Med 2001;27:1073-82.
74. Stanwell-Smith RE, Stuart JM, Hughes AO, et al. Smoking, the environment and meningococcal disease: a case-control study. Epidemiol Infect 1994;112:315-28.
75. Kriz P, Bobak M, Kriz B. Parental smoking, socioeconomic factors, and risk of invasive meningococcal disease in children: a population based case-control study. Arch Dis Child 2002;83:117-21.
76. Fischer M, Hedberg K, Cardosi P. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis 1997;16:979-83.
77. Hodgson A, Smith T, Gagneux S, et al. Risk factors for meningococcal meningitis in northern Ghana. Trans R Soc Trop Med 2001;95:477-80.
78. Cartwright K, Jones DM, Smith AJ, et al. Influenza A and meningococcal disease. Lancet 1991;338:554-7.
79. Stephens DS, Hajjeh RA, Baughman WS, et al. Aporadic meningocococcal disease in adults: results of a 5-year population-based study. Ann Intern Med 1995;123:937-40.
80. Moore PS, Hierholzer J, DeWitt W, et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA 1990;264:1271-5.
81. Young LS, LaForce FM, Head JJ, et al. A simultaneous outbreak of meningococcal and influenza infections. N Engl J Med 1972;287:5-9.
82. Salit IE. Meningococcaemia caused by serogroup W135. Association with hypogammaglobullnaemia. Arch Intern Med 1981;141:664-5.
83. Selik RM, Chu SY, Ward JW. Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Ann Intern Med 1995;123:933-6.
84. Lane PA. The spleen in children. Curr Opin Pediatr 1995;7:36-41.
85. Davidson RN, Wall RA. Prevention and management of patients without a spleen. Clin Microbiol Infect 2001;7:657-60.
86. Spickett GP, Bullimore J, Wallis J, et al. Northern region asplenia register - analysis of first two years. J Clin Pathol 1999;52:424-9.
87. Loggie BW, Hinchey EJ. Does splenectomy predispose to meningococcal sepsis? An experimental study and clinical review. J Pediatr Surg 1986;21:326-30.
88. Figueroa J, Andreoni J, Densen P. Complement deficiency states and meningococcal disease. Immunol Res 1993;12:295-311.
89. Hassig A, Borel JF, Ammann P. Essentielle hypokomplementamie. Pathologie Microbiologie 1964;27:527-42.
90. Fijen CAP, Kuijper EJ, te Bulte MT, et al. Assessment of complement deficiency in patients with meningococcal disease in the Netherlands. Clin Infect Dis 1999;28:105.
91. Platonov AE, Beloborodov VB, Vershinina IV. Meningococcal disease in patients with late complement component deficiency: studies in the U.S.S.R. Medicine 1993;72:374-92.
92. Hoare S, El-Shazalie O, Clark JE, et al. Investigation for complement deficiency following meningococcal disease. Arch Dis Child 2002;86:215-17.
93. Schlesinger M, Nave Z, Slater PE, et al. Prevalence of hereditary properdin, C7 and C8 deficiencies in patients with meningococcal infections. Clin Exp Immunol 1990;81:423-7.
94. Fijen CAP, van den Bogaard R, Schipper M, et al. Properdin deficiency: molecular basis and disease association. Mol Immunol 1999;36:863-7.
95. Hubacek JA, Stüber F, Fröhlich D, et al. The common functional C(-159)T polymorphism within the promoter region of the lipopotysaccharide receptor CD14 is not associated with sepsis development or mortality. Genes Immun 2000;1:405-7.
96. Hubacek JA, Stüber F, Fröhlich D, et al. Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med 2001;29:557-61.
97. Hibberd ML, Sumiya M, Summerfield JA, et al., Meningoccal Research Group. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet 1999;353:1049-53.
98. Summerfield JA, Sumiya M, Levin M, et al. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997;314:1229-36.
99. van der Pol WL, Huizenga TWJ, Vidarsson G, et al. Relevance of Fcγ receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 2001;184:1548-55.
100. Domingo P, Muñis-Diaz E, Baraldès MA, et al. Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. Am J Med 2002;112:19-25.
101. Teczan I, Berkel AI, Ersoy F, et al. Fcγ receptor allotypes in children with bacterial meningitis - a preliminary study. Turk J Pediatr 1998;40:533-8.
102. Westendorp RGJ, Langermans JA, Huizenga TWJ, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997;349:170-3.
103. Nadel S, Newport M, Booy R, et al. Variation in the tumour necrosis factor-α gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996;174:878-80.
104. Appoloni O, Dupont E, Vandercruys M, et al. Association of tumor necrosis factor-2 allele with plasma tumor necrosis factor-α levels and mortality from septic shock. Am J Med 2001;110:486-8.
105. Fijen JW, Tulleken JE, Hepkema BG, et al. The influence of tumor necrosis factor-α and interleukin-10 gene promoter polymorphism on the inflammatory response in experimental human endotoxemia. Clin Infect Dis 2001;33:1601-3.
106. Fang XM, Schröder S, Hoeft A, et al. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999;27:1330-4.
107. Read RC, Camp NJ, di Giovine FS, et al. An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. J Infect Dis 2000;182:1557-60.
108. van Deventer SJH. Cytokine and cytokine receptor polymorphisms in infectious disease. Intensive Care Med 2000;26:S98-102.
109. Booy R, Nadel S, Hibberd ML, et al. Genetic influence on cytokine production in meningococcal disease. Lancet 1997;349:1176.
110. Stüber F. Effects of genomic polymorphisms on the course of sepsis: is there a concept for gene therapy? J Am Soc Nephrol 2001;12:S60-4.
111. Hermans PW, Hibberd ML, Booy R, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal research group. Lancet 1999;354:556-60.
112. Nadel S. Helping to understand studies examining genetic susceptibility to sepsis [editorial]. Clin Exp Immunol 2002;127:191-2.
113. Fisher CJ, Agosti JM, Opal SM, et al. Tumor necrosis factor receptor:Fc fusion protein for septic shock. N Engl J Med 1996;334:1697-702.
114. Lehner PJ, Davies KA, Walport MJ, et al. Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipolysaccharide release. Lancet 1992;340:1379-81.
115. 21, for adjunctive treatment of children with severe meningococcaemia. Crit Care Med 2001;29:S130-5.
116. Smith OP, White B, Vaughan D, et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997;350:1590-3.
117. Duncan A. New therapies for severe meningococcal disease but better outcomes? Lancet 1997;350:1565-8.
118. Leclerc F, Cremer R, Leteurtre S, et al. Protein C concentrate and recombinant tissue plasminogen activator in meningococcal septic shock. Crit Care Med 2000;28:1694-5.
119. Gerson WT, Dickerman JD, Bovill EG, et al. Severe acquired protein C deficiency with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics 1993;91:418-22.
120. 21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet 2000;356:961-7.
121. Matthay M. Severe sepsis - a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 2001;344:759-62.
122. Glauser MP. Pathophysiologic basis of sepsis: considerations for future strategies of interevention. Crit Care Med 2001;28:S4-8.
123. Cohen J. Meningococcal disease as a model to evaluate novel anti-sepsis strategies. Crit Care Med 2000;28:S64-7.